Research programme: small molecule therapeutics - Amphilix AG
Latest Information Update: 05 Nov 2020
At a glance
- Originator Amphilix AG
- Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer; Eye disorders; Inflammation
Most Recent Events
- 02 Nov 2020 Early research in Cancer in Switzerland (unspecified route)
- 02 Nov 2020 Early research in Eye disorders in Switzerland (unspecified route)
- 02 Nov 2020 Early research in Inflammation in Switzerland (unspecified route)